Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Defosbarasertib - AstraZeneca/Pfizer

Next Previous
Drug Profile

Defosbarasertib - AstraZeneca/Pfizer

Alternative Names: AZD 1152 hQPA; AZD-2811; AZD2811 nanoparticle

Latest Information Update: 28 May 2025

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator AstraZeneca; BIND Therapeutics
  • Developer AstraZeneca; Pfizer
  • Class Acetamides; Amines; Antineoplastics; Fluorinated hydrocarbons; Fluorobenzenes; Pyrazoles; Quinazolines; Small molecules
  • Mechanism of Action Aurora kinase B inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Small cell lung cancer
  • Phase I/II Acute myeloid leukaemia
  • No development reported Diffuse large B cell lymphoma; Non-small cell lung cancer
  • Discontinued Solid tumours

Most Recent Events

  • 28 May 2025 No recent reports of development identified for preclinical development in Non-small-cell-lung-cancer in United Kingdom (IV)
  • 28 May 2024 No recent reports of development identified for preclinical development in Diffuse large B cell lymphoma in USA (IV)
  • 08 Apr 2022 Pharmacodynamics data from preclinical studies in Solid tumours presented at the 113th Annual Meeting of the American Association for Cancer Research (AACR-2022)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top